ArticleBMC veterinary research2025
Identification of immunomodulating properties of postbiotics from lactobacilli using the zebrafish (Danio rerio) model.
Article in BMC veterinary research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND &
objectivesProbiotics are increasingly used in the pet industry to enhance the health and well-being of companion animals. Among them, Lactobacillus strains and their metabolites have demonstrated the ability to maintain immune homeostasis, modulate immune responses, and exhibit antiviral properties. Despite growing interest in postbiotics, non-viable microbial products or metabolic byproducts, scientific literature on their effects remains limited. This study investigates the immunomodulatory and antiviral properties of three postbiotics derived from heat-inactivated Lactobacillus strains using an adult zebrafish (Danio rerio) model challenged with viral hemorrhagic septicemia virus (VHSV).
methodsA total of 330 zebrafish were assigned to five groups: a non-challenged control (C1), a VHSV-challenged control (C2), and three experimental groups supplemented with one of three heat-treated Lactobacillus strains at the same dosage (Lacticaseibacillus paracasei HA-108; Lactiplantibacillus plantarum HA-119 or Lactobacillus helveticus HA-122). Fish were fed at 4% of biomass for 21 days. Following this period, a subset of the fish was used for immune gene expression profiling and histological examination of the gut and kidney. The remaining fish were challenged with VHSV and monitored for survival over 10 days.
resultsAll postbiotics treatments modulated immune responses, with L. plantarum HA-119 showing the most pronounced effects, including upregulation of key immune genes such as Il1β and Ifn-γ, indicative of anti-inflammatory and antiviral activity. Histological analysis revealed no significant changes in goblet cell density or villi height, supporting the safety of the postbiotics. Survival rates were significantly higher in the L. plantarum HA-119 and L. helveticus HA-122 groups compared to the VHSV control.
conclusionsThese findings, derived from a well-established zebrafish model, suggest that postbiotics from Lactobacillus strains may enhance antiviral immunity and overall health in vertebrates, supporting their potential as safe, effective microbial-based nutritional interventions in pet nutrition.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.